World-class Services for Life-Changing Products
Our subject matter experts partner with you to help accelerate your discovery program toward the clinic and commercialization with our best in-class experience and capabilities in medicinal chemistry, in vitro pharmacology and structural biology.
Whether you require a particular expertise and capability to integrate with your internal discovery team or a complete, experienced integrated small molecule discovery team, Curia can provide a high-performance solution to help turn your vision into reality.
From discovery to development and commercial manufacturing, we seamlessly integrate broad capabilities to provide an accelerated path to commercialization. Curia, Your Partner on the Journey from Curiosity to Cure®.
Biology and Medicinal Chemistry
Dedicated discovery biology, chemistry, and analytical teams ensure a seamless transition for your project from drug discovery to development.
- Recombinant Protein Production
- Assay Design and Development
- Cell-Based Assay Technologies
- Synthetic and Medicinal Chemistry
- Drug Metabolism and PharmacoKinetic (DMPK) Studies
- Structural Biology
- Computer-Aided Drug Design (CADD)
- Discovery Biology
- High-Throughput Screening
Hit-to-Lead and Lead optimization
We identify hits with the desired mechanism of action and develop new chemical entities and intellectual property to provide improved preclinical and clinical candidates. Our highly experienced and successful medicinal chemists routinely:
- Synthesize new analogs using multistep processes and high purity standards (for a lead series).
- Combine computational, structural and biological assay results to design new compounds.
- Move you quickly with specialized analytical and solid-state services.
- Advance your proprietary compounds to clinical testing with intellectual property support.
Notable Discovery Experience and Technology
Curia’s unique, high-purity and cost-effective synthetic compound libraries are designed to yield lead-like hits and provide advantaged starting points for hit-to-lead programs.
Our high-performance protein crystallography, high-throughput crystal soaking and co-crystallization capabilities are powerful tools to identify structure-based drug development (SBDD) enabled targets and hits from a compound library screening campaign.
Curia’s state-of-the-art high content imaging and analysis experience and capabilities are available to develop and empower multi-parametric high content screening campaigns at true HTS scales. Click the links below to review some recent examples of Curia’s innovation, including in high content analysis.
The original innovator of contract medicinal chemistry, Curia provides access to the worlds’ most experienced contract medicinal chemistry team. Tenures at Curia of >20 years are common within the team.
Discovery
Identify, refine and secure breakthrough compounds. Your success is our story.
